1488.70
0.72%
Karvy
Outlook & Valuation: We downgrade our revenue estimates for FY21E / FY22E by 4.6% / 4.6% to Rs. 32.9 Bn / Rs. 36.3 Bn for FY21E / FY22E. We downgrade our EBITDA margins for FY21E / FY22E by 50 bps to 20.6%/21.9% due to fixed nature of personal cost.
default
GlaxoSmithKline Phar.. has an average target of 1279.50 from 2 brokers.
Recommended
More from GlaxoSmithKline Pharmaceuticals Ltd.